Supernus Pharmaceuticals

$24.15
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.97 (-3.86%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell SUPN and other stocks, options, and ETFs commission-free!

About SUPN

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD. The listed name for SUPN is Supernus Pharmaceuticals, Inc. Common Stock.

CEO
Jack A. Khattar
Employees
464
Headquarters
Rockville, Maryland
Founded
2005
Market Cap
1.37B
Price-Earnings Ratio
10.58
Dividend Yield
—
Average Volume
808.76K
High Today
$25.58
Low Today
$23.98
Open Price
$25.24
Volume
1.15M
52 Week High
$31.99
52 Week Low
$13.12

SUPN Earnings

$0.28
$0.43
$0.59
$0.74
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.52 per share
Actual
$0.57 per share
Replay Earnings Call

You May Also Like

STRR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure